Business Context and Reporting Period
Company: Firefly Neuroscience, Inc. (Nasdaq: AIFF)
Filing Type: Form 8-K (Current Report)
Report Date: December 16, 2025
Event: Entry into a Material Definitive Agreement regarding warrant restructuring.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial data points relate to the warrant exchange transaction:
- Warrants Surrendered: 800,000 total (400,000 at $3.50 exercise price; 400,000 at $4.00 exercise price).
- New Warrants Issued: 800,000 total at a reduced exercise price of $0.50 per share.
- Potential Proceeds: Approximately $400,000 in aggregate gross proceeds if all new warrants are exercised.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes
The Company entered into a Warrants Cancellation and Exchange Agreement with certain investors. This agreement modifies the terms of warrants issued on June 16, 2025, by significantly reducing the exercise price from $3.50 and $4.00 to $0.50 per share. The filing notes no material relationships existed between the Company and the investors prior to this transaction.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to use proceeds from the potential exercise of the new warrants for working capital. The agreement includes a requirement for warrant holders to exercise the new warrants within ten business days of the Exercise Date to the maximum extent permitted by beneficial ownership limitations, with remaining warrants to be exercised thereafter until fully exercised.
Risks/Contingencies: The transaction relies on exemptions from registration under Section 4(a)(2) and Rule 506(b) of the Securities Act for the private placement, and Section 3(a)(9) for the warrant exchange. Actual proceeds are contingent upon the exercise of the new warrants.
Investor Verification Checklist
- Verify the current market price of AIFF common stock relative to the new $0.50 exercise price to assess immediate dilution potential.
- Review the "Beneficial Ownership Limitation" defined in the New 2025 Warrants to understand constraints on immediate exercise.
- Confirm the identity of the "Warrant Investors" to assess concentration of ownership.
- Examine the full text of the Warrants Cancellation and Exchange Agreement (Exhibit 10.1) for specific exercise dates and conditions.